Limits...
CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.

Chen S, Song X, Chen Z, Li X, Li M, Liu H, Li J - PLoS ONE (2013)

Bottom Line: We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate.Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC.Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Tumor Surgery, Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou, China.

ABSTRACT

Objective: CD133 has recently been reported as a marker of cancer stem-like cells in colorectal cancer (CRC). However, its predictive value in CRC still remains controversial. In this study, we aimed to evaluate the association between the expression of CD133 and clinicopathological features and the outcome of CRC patients by performing a meta-analysis.

Methods: A comprehensive literature search for relevant studies published up to December 2012 was performed using PubMed, MEDLINE and ISI Web of Science. Only articles in which CD133 antigen was detected in situ localisation by immunohistochemical staining were included. This meta-analysis was done using RevMan 4.2 software.

Results: We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate. In a random-effects model, the results showed that CD133-high expression in colorectal cancer was an independent prognostic marker correlating with both OS rate (RR = 0.67, 95%CI 0.54-0.82, P<0.01) and disease free survival (DFS) rate (RR = 0.71, 95%CI 0.52-0.96, P = 0.03). CD133-high expression was also associated with more T3,4 tumor invasion, N positive and vascular invasion cases, corresponding to a risk difference of 1.12 (95%CI 1.01-1.23, P = 0.03), 1.31 (95%CI 1.06-1.63, P = 0.01) and 1.24 (95%CI 1.08-1.41, P<0.01), respectively. However, when types of histology, lymphatic invasion and distant metastasis were considered, CD133 overexpression was not significantly related with these clinicopathological parameters.

Conclusion: Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC. Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.

Show MeSH

Related in: MedlinePlus

Flowchart of selection of studies for inclusion in meta-analysis.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3569427&req=5

pone-0056380-g001: Flowchart of selection of studies for inclusion in meta-analysis.

Mentions: Detailed search steps were described in Figure 1. The initial search algorithm retrieved a total of 146 studies according to the inclusion/exclusion criteria stated above. After titles and abstracts were previewed, only 35 identified studies concerning CD133 and the risk of CRC were further evaluated. Of the published studies, 20 reports were excluded: five were about CD133 gene expression[23]–[27], eight were about CD133 mRNA expression[28]–[35], another five didn’t provid OS or DSF rate[12], [13], [16], [36], [37] and the other two duplicate reports on the same population[14], [38]. Eventually, a total of 15 observational retrospective studies met the predefined inclusion criteria including about 2297 participants[15], [39]–[52]. All these studies evaluated the expression of CD133 and risk of colorectal cancer by immunohistochemical staining method(Table 1).


CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.

Chen S, Song X, Chen Z, Li X, Li M, Liu H, Li J - PLoS ONE (2013)

Flowchart of selection of studies for inclusion in meta-analysis.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3569427&req=5

pone-0056380-g001: Flowchart of selection of studies for inclusion in meta-analysis.
Mentions: Detailed search steps were described in Figure 1. The initial search algorithm retrieved a total of 146 studies according to the inclusion/exclusion criteria stated above. After titles and abstracts were previewed, only 35 identified studies concerning CD133 and the risk of CRC were further evaluated. Of the published studies, 20 reports were excluded: five were about CD133 gene expression[23]–[27], eight were about CD133 mRNA expression[28]–[35], another five didn’t provid OS or DSF rate[12], [13], [16], [36], [37] and the other two duplicate reports on the same population[14], [38]. Eventually, a total of 15 observational retrospective studies met the predefined inclusion criteria including about 2297 participants[15], [39]–[52]. All these studies evaluated the expression of CD133 and risk of colorectal cancer by immunohistochemical staining method(Table 1).

Bottom Line: We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate.Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC.Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Tumor Surgery, Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou, China.

ABSTRACT

Objective: CD133 has recently been reported as a marker of cancer stem-like cells in colorectal cancer (CRC). However, its predictive value in CRC still remains controversial. In this study, we aimed to evaluate the association between the expression of CD133 and clinicopathological features and the outcome of CRC patients by performing a meta-analysis.

Methods: A comprehensive literature search for relevant studies published up to December 2012 was performed using PubMed, MEDLINE and ISI Web of Science. Only articles in which CD133 antigen was detected in situ localisation by immunohistochemical staining were included. This meta-analysis was done using RevMan 4.2 software.

Results: We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate. In a random-effects model, the results showed that CD133-high expression in colorectal cancer was an independent prognostic marker correlating with both OS rate (RR = 0.67, 95%CI 0.54-0.82, P<0.01) and disease free survival (DFS) rate (RR = 0.71, 95%CI 0.52-0.96, P = 0.03). CD133-high expression was also associated with more T3,4 tumor invasion, N positive and vascular invasion cases, corresponding to a risk difference of 1.12 (95%CI 1.01-1.23, P = 0.03), 1.31 (95%CI 1.06-1.63, P = 0.01) and 1.24 (95%CI 1.08-1.41, P<0.01), respectively. However, when types of histology, lymphatic invasion and distant metastasis were considered, CD133 overexpression was not significantly related with these clinicopathological parameters.

Conclusion: Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC. Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.

Show MeSH
Related in: MedlinePlus